Questions to Ask Before Hiring an AI Healthcare Data Partner

For: A Series A digital health founder who has already shipped a working product but now needs to integrate real clinical or pharmacy data pipelines — EHR feeds, HL7/FHIR interfaces, or real-time prescription streams — and is evaluating vendors who claim deep healthcare data experience but whose demos always use synthetic or de-identified CSV exports

Every healthcare AI vendor's demo looks the same: a clean dashboard, a de-identified CSV, a model that flags something useful. The trouble starts at week three of the integration, when a real HL7 v2.5 ADT^A08 message arrives with a malformed PID-3 segment, the parser silently drops the patient identifier, and your AI starts attaching insights to the wrong record. At that point you discover whether your vendor has actually worked with live clinical data or just packaged a Kaggle notebook as enterprise healthcare AI.

The hard truth: HIPAA familiarity is table stakes. Every vendor memorizes the checklist. What separates a real AI healthcare data partner from a confident pretender is operational scar tissue — documented failures on live feeds, and the architectural decisions those failures forced.

If you're a Series A digital health founder evaluating vendors for EHR integrations, HL7/FHIR interfaces, or prescription streams, here are the questions to ask. Each one is designed to be hard to fake.

The 14 questions

1. Walk me through a production failure you had on a live HL7 or FHIR feed. What broke, how did you detect it, and what changed in your pipeline architecture?

Why it matters: This is the single most diagnostic question on the list. Anyone who has actually run pipelines against live clinical data has stories. Anyone who hasn't will pivot to generalities.

Good answer: A specific story. "We had an Epic feed where MSH-9 was set to ORU^R01 but the OBX segments contained ADT data because of a downstream interface engine misconfiguration. Our schema validator passed it. We caught it because our downstream ML feature store flagged a 40x spike in null lab values. We added message-type-vs-payload consistency checks at ingest and a circuit breaker that pauses model inference when feature distributions shift beyond a threshold."

Red flag: "We have robust error handling and 24/7 monitoring." That's a brochure, not an answer.

2. Which FHIR versions do you support in production, and how do you handle a hospital that's still on DSTU2?

Why it matters: FHIR R4 is the standard most US payers and large systems target now, but plenty of provider integrations still run DSTU2 or STU3. A real partner has dealt with version mismatches.

Good answer: They name versions, describe a translation layer or canonical internal model, and acknowledge specific resource-level differences that bit them (e.g., changes to MedicationRequest between STU3 and R4).

Red flag: "We support FHIR." Singular, no version, no nuance.

3. How do you enforce PHI boundaries between your AI training data, your inference pipeline, and your logging infrastructure?

Why it matters: Most accidental PHI leaks happen in logs, error traces, and model debugging artifacts — not in the primary data path. This is where shortcuts surface.

Good answer: Specifics about field-level tagging, log scrubbers (with the regex or library named), separate VPCs or accounts for training vs. inference, and a documented policy on what model artifacts are allowed to contain. Bonus if they mention how they handle PHI in prompts when LLMs are involved.

Red flag: "All data is encrypted at rest and in transit." That's necessary and irrelevant to the question.

4. Show me your BAA. Who are your subprocessors?

Why it matters: If they use OpenAI, Anthropic, Pinecone, or any managed service in the PHI path, you need to know — and you need their BAAs with those providers. Many vendors quietly route PHI through APIs that aren't covered.

Good answer: A list. Named subprocessors. Clear statement on which ones touch PHI and which BAAs are in place. If they use LLMs, they explain whether it's a HIPAA-eligible deployment (Azure OpenAI, AWS Bedrock with BAA, self-hosted).

Red flag: Vagueness about LLM providers. "We use AI models" is not an answer when PHI is involved.

5. What's your strategy when an upstream HL7 feed changes without notice?

Why it matters: Hospital IT changes interface engine configs without telling vendors. It will happen to you. The question is whether your partner has built for it.

Good answer: Schema drift detection, statistical monitoring on field-level distributions, automated alerts when message volume or shape changes, and a manual review queue before model output is trusted again.

Red flag: "We work closely with the hospital IT team." You will not always have that luxury.

6. How do you handle patient identity resolution across feeds?

Why it matters: The same patient appears in EHR data, pharmacy data, and claims data with different identifiers. Bad linkage means bad AI output, and in clinical contexts, that's a safety issue.

Good answer: They've used or built an EMPI/MPI approach, can discuss probabilistic vs. deterministic matching, and have a documented false-match rate they monitor.

Red flag: Treating identity resolution as a join on patient_id.

7. Walk me through how you'd integrate a real-time prescription stream from a pharmacy benefits manager.

Why it matters: Forces them to describe NCPDP SCRIPT, eligibility checks, formulary lookups, and the operational realities of PBM integrations — or expose that they've never done it.

Good answer: Mentions NCPDP standards, talks about handling rejections and reversals, discusses idempotency for retries, and acknowledges the latency budget for real-time use cases.

Red flag: They describe it as a generic streaming problem with Kafka.

8. What does your model evaluation look like when ground truth is noisy or delayed by months?

Why it matters: Clinical outcomes don't have clean labels. A vendor accustomed to Kaggle datasets has never had to build evaluation under these conditions.

Good answer: Talks about proxy metrics, chart review sampling, clinician-in-the-loop validation, and how they handle concept drift when the truth label arrives 90 days later.

Red flag: AUC and F1 with no discussion of label quality.

9. How do you handle drug-drug interactions, allergies, or other clinical safety logic?

Why it matters: If your product touches medications, the AI must defer to deterministic clinical rules where applicable. This is a place LLM hallucinations can hurt people.

Good answer: They distinguish between AI-generated suggestions and deterministic safety checks. They reference data sources like First Databank, Lexicomp, or RxNorm and explain how they keep these current.

Red flag: "Our model has learned drug interactions from training data."

10. What's your incident response process for a suspected PHI exposure?

Why it matters: HIPAA breach notification has a 60-day clock. A real partner has a runbook.

Good answer: Named roles, a documented runbook, log retention policies that allow forensic reconstruction, and experience (even hypothetical tabletop exercises) walking through it.

Red flag: "We'd notify you immediately." Then what?

11. Who on your team has shipped a healthcare AI system in production, and what was their specific role?

Why it matters: Vendor sales decks list "healthcare experience" without specifying whether that means the CEO once sold to a hospital or an engineer has actually parsed CCDA documents at 3am.

Good answer: Named people, specific projects, specific roles. You can ask to talk to those engineers, not just account managers.

Red flag: Generic credentials. "Our team has 50+ years of combined healthcare experience."

12. How do you version data, models, and the linkage between them for auditability?

Why it matters: When a clinician questions an AI output six months from now, you need to reconstruct exactly which model version saw which data version with which features. Regulators may ask too.

Good answer: They name tools (DVC, MLflow, Weights & Biases, custom) and describe how they tie a specific inference back to a specific model artifact and feature snapshot.

Red flag: "We keep our models in Git."

13. What's your approach when the data is just wrong — not malformed, but clinically implausible?

Why it matters: A height of 6 cm or a heart rate of 4000 happens. These pass schema validation. They corrupt models.

Good answer: Range checks, clinical plausibility rules, outlier flagging, and a clear policy on whether to drop, impute, or quarantine.

Red flag: "Our model is robust to outliers."

14. What is this approach bad at? Where would you tell us not to use it?

Why it matters: Honest vendors know their limits. Salespeople don't.

Good answer: Specific use cases they'd decline. Specific failure modes you should expect. Specific places where a human must stay in the loop.

Red flag: "Our system handles everything."

How to run the interview

A few practical notes on conducting these conversations:

• Get the engineers on the call. Sales answers will sound polished. Engineering answers will be specific, occasionally hesitant, and far more useful.
• Ask follow-ups two layers deep. "You said you have schema drift detection — what specifically triggers an alert, and who gets paged?" Real systems survive this. Marketing language doesn't.
• Ask for a sample log line (scrubbed). It tells you a lot about how seriously they treat the PHI boundary.
• Reference-check on the integrations, not the outcomes. Don't ask references "did it work?" Ask "what broke during integration, and how did the vendor respond?"

How CodeNicely can help

We built HealthPotli, an e-pharmacy platform with AI-driven drug interaction checking, which forced us through most of the questions above: prescription data ingestion, drug database integration (RxNorm-style mappings), real-time interaction logic that defers to deterministic clinical rules rather than relying on LLM recall, and PHI boundary enforcement across an AI inference path. If your situation is similar — a working product that now needs to handle live clinical or pharmacy data with safety-critical reasoning on top — that's the engagement worth asking us about.

We're honest about what we're not: we don't sell pre-trained clinical models, and we don't promise that AI replaces clinician judgment on safety-critical paths. We build the data infrastructure, integration layer, and AI tooling around your clinical product. More on our approach at AI Studio and our work with startups.

Frequently Asked Questions

What's the difference between a HIPAA-compliant vendor and one that's actually built production healthcare AI?

HIPAA compliance is a checklist anyone can pass with the right legal and security setup. Production healthcare AI experience shows up in messy places: HL7 parsing edge cases, FHIR version translation, PHI scrubbing in logs and LLM prompts, and clinical safety logic that doesn't rely on model outputs. Ask for documented failure modes, not certifications.

Should I trust a vendor whose demos use synthetic data?

Synthetic data demos are fine for showing UX. They're insufficient evidence of production readiness. Before signing, ask to see how they handle real-world failure scenarios — malformed HL7 messages, FHIR version mismatches, identity collisions — even if walked through verbally rather than live.

Do I need a vendor with my exact EHR experience (Epic, Cerner, athenahealth)?

Helpful but not essential. What matters more is whether they've worked with HL7 v2 and FHIR generically and have a canonical internal data model that abstracts EHR-specific quirks. A vendor who's only ever integrated one EHR may have built brittle assumptions in.

How long does a real EHR or pharmacy data integration take?

It depends heavily on the data source, the partner hospital's IT cooperation, and the scope of AI on top. Rather than work from a generic estimate, contact CodeNicely for a personalized assessment based on your specific integration targets.

What questions should I ask references for a healthcare AI vendor?

Skip "were you happy?" Ask: what broke during integration, how did the vendor respond, what did they catch that you missed, and what would you do differently next time. The texture of those answers tells you more than any case study.